Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The CooperCOO -0.59%89 3-Year EBITDA Growth Rate is 5.70% as of Apr. 2026, which is 57% below its 10-year median of 13.30. GuruFocus rates COO with a GF Score™ of 89/100 and a GF Value™ of $101.45 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 691 Medical Devices & Instruments companies, The Cooper ranks worse than 54.56% on this metric.
During the past 12 months, The Cooper's average EBITDA Per Share Growth Rate was -17.80% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 5.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 10.80% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 8.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of The Cooper was 74.50% per year. The lowest was -156.50% per year. And the median was 13.30% per year.
The Cooper (NAS:COO) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
The Cooper 3-Year EBITDA Growth Rate Related Terms
COO vs SOLV, ALGN, BAX: 3-Year EBITDA Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, The Cooper's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Cooper 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, The Cooper's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where The Cooper's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 5.70% mean?
The Cooper (COO) has a 3-Year EBITDA Growth Rate of 5.70% as of Apr. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for The Cooper and its competitors. This is 57% below median its historical median of 13.30. According to the industry distribution chart, The Cooper ranks #377 out of 691 companies in the Medical Devices & Instruments industry, placing it in the top 54.6%.
Is The Cooper's 3-Year EBITDA Growth Rate too high?
The Cooper's current 3-Year EBITDA Growth Rate of 5.70% is 57% below median its 10-year median of 13.30. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.10. The Cooper's value of 5.70% is 29.6% below this industry median. Based on the distribution chart, The Cooper ranks #377 out of 691 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, The Cooper has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Cooper's 3-Year EBITDA Growth Rate compare to SOLV and ALGN?
According to the Medical Devices & Instruments industry distribution chart, The Cooper ranks #377 out of 691 companies for 3-Year EBITDA Growth Rate. This places The Cooper in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.10. The Cooper's value of 5.70% is 29.6% below this benchmark. While the company's 10-year median is 13.30 vs. the industry median of 8.10, The Cooper has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Cooper's current 3-Year EBITDA Growth Rate of 5.70% is 29.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for The Cooper and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Cooper's current 3-Year EBITDA Growth Rate is 5.70%, which is 57% below median its own 10-year median of 13.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Cooper stock overvalued right now?
Based on GuruFocus' analysis, The Cooper (COO) is currently considered Modestly Undervalued. The stock's GF Value™ is $101.45, compared to a current price of $72.65 — trading 28.4% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 5.70%, which is 57% below median its 10-year median of 13.30 and 29.6% below the Medical Devices & Instruments industry median of 8.10. The Cooper's overall GF Score™ is 89/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For The Cooper (COO), the current 3-Year EBITDA Growth Rate is 5.70% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Cooper (COO) Overvalued in 2026?
Based on GuruFocus' analysis, The Cooper stock appears to be undervalued.
The current stock price of $72.65 is trading 28.4% below its estimated GF Value™ of $101.45.
GuruFocus considers The Cooper to be Modestly Undervalued.
Key valuation signals for COO:
3-Year EBITDA Growth Rate: 5.70% (57% below median its 10-year median of 13.30)
GF Value™: $101.45 vs. price of $72.65 (28.4% below fair value)
Industry Position: 29.6% below the Medical Devices & Instruments median (#377 of 691)
No single metric tells the full story. See the COO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
89GF Score
Get the complete analysis for COO
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COO has been successfully added to your 
